Table 3

TPE procedures performed according to clinical indications and reported complications

Category (ASFA)PatientsMedian age, yearsMaleMean TPE sessions (SD)Median Hct, %Wt, kgMedian TPE volume, mLComplicationsHypotensionHypocalcaemiaAllergic reactionCRBSI
CNS disorders
NMOSD (acute)II28 (51%)39.9 (13–63)5 (18%)4.75 (0.8)36 (28–48)57 (36–111)2244 (1720–3455)11 (39%)6 (21%)3 (11%)0 (0%)3 (11%)
Acute CNS demyelinating disease (TM)II8 (15%)33.5 (22–56.6)2 (25%)3.375 (1.8)35 (31–40)52 (42–80)2121 (1744–2943)4 (50%)1 (13%)2 (25%)0 (0%)1 (13%)
Multiple sclerosisII3 (5%)38 (34–42)1 (33.3%)5 (0)40 (33–47)74 (65–79)2596 (2327–2912)0 (0%)0 (0%)0 (0%)0 (0%)0 (0%)
CRIONN/A2 (4%)26.75 (26.5–27)2 (100%)5 (0)46 (43–47)62(62-64)2150 (2100–2199)2 (100%)2 (100%)0 (0%)0 (0%)0 (0%)
ADEMII1 (2%)26 (—)1 (100%)1 (—)39 (—)64 (—)2517 (—)1 (100%)0 (0%)0 (0%)1 (100%)0 (0%)
NMDARI1 (2%)24 (—)0 (0%)5 (—)31 (29–34)45 (—)2100 (—)1 (100%)0 (0%)0 (0%)0 (0%)1 (100%)
PNS and NMJ disorders
GBS (AIDP)I6 (11%)57 (19–60.5)3 (50%)4.25 (1.6)36 (3–44)51 (45–68)2273 (2047–2745)2 (33.3%)2 (33.3%)0 (0%)0 (0%)0 (0%)
CIDPI2 (4%)32.75 (24–41.5)2 (100%)4.5 (0.7)44 (42–45)65.5 (60–71)2369 (2274–2463)1 (50%)0 (0%)0 (0%)0 (0%)1 (50%)
MGI4 (7%)45.65 (45.3–46)0 (0%)5 (0)33 (30–40)54 (52–61)2270 (2000–2475)1 (25%)1 (25%)0 (0%)0 (0%)0 (0%)
All patients5541 (13–63)16 (29%)4.536 (28–48)56 (36–111)2245 (1720–3455)23 (42%)12 (22%)5 (9%)1 (2%)6 (11%)
  • ADEM, acute disseminated encephalomyelitis; AIDP, acute inflammatory demyelinating polyneuropathy; ASFA, American Society for Apheresis; CIDP, chronic inflammatory demyelinating polyneuropathy; CNS, central nervous system; CRBSI, catheter-related blood stream infection; CRION, chronic relapsing inflammatory optic neuropathy; GBS, Guillain-Barre syndrome; Hct, haematocrit; MG, myasthenia gravis; NMDAR, N-methyl-D-aspartate receptor ; NMJ, neuromuscular junction; NMOSD, neuromyelitis optica spectrum disorders; PNS, peripheral nervous system; TM, transverse myelitis; TPE, therapeutic plasma exchange.